In a study of ERBB2-amplified or -mutant lung cancers, co-treatment of lung cancer cells with T-DM1 and the irreversible pan-HER kinase inhibitors neratinib increased uptake of T-DM1, but when the reversible HER2 inhibitor lapatinib was used, a decreased uptake of T-DM1 was seen [33]. The gene discussed is ERBB2; the disease is lung carcinoma.